MedTrace Logo

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

NCT01084005 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2014-01-29

Study results available
· View outcomes & findings →

Summary

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

linagliptin

patients receive linagliptin 5 mg tablets once daily

DRUG

placebo

patients receive placebo matching linagliptin 5 mg once daily

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-06-30

Countries

  • Australia
  • Canada
  • Denmark
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01084005 on ClinicalTrials.gov